BioSpace News Archive

aTyr Pharma, Inc. announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr’s common stock, each with an exercise price of $1.86 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on May 22, 2024, the effective date of the grants.

OpGen, Inc. announced that it received a notice from The Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5250 due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024, which serves as an additional basis for delisting the Company’s securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company’s securities on Nasdaq.

Scinai Immunotherapeutics Ltd. announced the receipt of an additional Nasdaq Staff determination letter regarding noncompliance with the minimum shareholders’ equity required for continued listing and a hearing with the Nasdaq Hearings Panel to present a plan for the Company to regain compliance.

Nevro Corp. announced that on May 7, 2024, the Compensation Committee of the Company’s Board of Directors granted inducement restricted stock unit awards covering 59,460 shares of Nevro’s common stock to twenty-six new non-executive employees to induce them to accept employment with Nevro.

Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces a publication in the Journal of Molecular Metabolism.

Nicox SA, an international ophthalmology company, convenes an ordinary shareholder meeting on Friday June 28th, 2024 at 2:30 pm CEST in the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.

Regulatory News: Innate Pharma SA announced that five abstracts with Innate’s drug candidates have been accepted for the American Society of Clinical Oncology 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.

Dizal announced new findings from a biomarker study in non-small cell lung cancer patients with exon 20 insertion mutations, highlighting sunvozertinib as an effective treatment for this patient population.

Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid tumors in the United States.